Palbociclib is a targeted therapy that inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), thereby arresting tumour cell proliferation in the G1 phase of the cell cycle.
Recommended for:
Postmenopausal women with HR-positive, HER2-negative breast cancer
First-line therapy in combination with aromatase inhibitors
Use with fulvestrant in patients with disease progression after hormone therapy
Prescribed and monitored by oncologists only
Locally advanced or metastatic HR-positive, HER2-negative breast cancer
First-line endocrine-based therapy
Second-line after progression on prior hormonal therapy
Taken orally once daily for 21 consecutive days followed by a 7-day rest period (28-day cycle). Dosage and duration depend on the patient’s clinical condition and co-administered therapies, and are determined by the treating physician.
Contraindications:
Hypersensitivity to palbociclib
Severe hepatic impairment
Pregnancy and breastfeeding
Paediatric use
Concomitant use with strong CYP3A inhibitors
Side Effects:
Neutropenia
Leukopenia
Anaemia
Fatigue
Nausea
Diarrhoea
Temporary hair loss (alopecia)
Upper respiratory tract infections
